AXL

Aravive To Participate in Piper’s 34th Annual Healthcare Conference

Retrieved on: 
Monday, November 21, 2022
GAS6, AXL, Cancer, Royal commission, Platinum, European Commission, Metastasis, Therapy, Ovarian cancer, FDA, Real estate, Pharmaceutical industry

If you are interested in requesting a 1x1 meeting at the respective conference, please contact your bank/conference representative.

Key Points: 
  • If you are interested in requesting a 1x1 meeting at the respective conference, please contact your bank/conference representative.
  • Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease.
  • Batiraxcept has been granted Fast Track Designation by the U.S. FDA and Orphan Drug Designation by the European Commission in platinum resistant recurrent ovarian cancer.
  • The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016.

Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement

Retrieved on: 
Wednesday, November 16, 2022
GAS6, AXL, Listing Rules, Cancer, Royal commission, Platinum, European Commission, Arav, Metastasis, Therapy, Ovarian cancer, FDA, Pharmaceutical industry

HOUSTON, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company),a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the receipt of a formal notification from the Staff at The Nasdaq Stock Market, LLC (Nasdaq) on November 10, 2022 that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1).

Key Points: 
  • HOUSTON, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company),a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the receipt of a formal notification from the Staff at The Nasdaq Stock Market, LLC (Nasdaq) on November 10, 2022 that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1).
  • The Company was previously notified by the Staff at Nasdaq on August 9, 2022 that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules.
  • Since then, the Staff at Nasdaq has determined that for 11 consecutive business days, from October 27, 2022 to November 10, 2022, the closing bid price of the Companys common stock has been at $1.00 per share or greater.
  • Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1) and this matter is now closed.

Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, November 10, 2022
Platinum, Nivolumab, Serum, Communication, Research, Risk, Population, BLA, US, Company, Biologics license application, CMC, Review, Forward-looking statement, GAS6, Toxic leukoencephalopathy, Pancreatic cancer, Cancer, Genta (company), European Commission, Paclitaxel, SEC, Science, Patient, AXL, COVID-19, Private Securities Litigation Reform Act, Tectonic evolution of the Aravalli Mountains, PDAC, Achievement, Clinical trial, Terminology, DABT, ITT, Metastasis, FDA, GLOBE, PFS, PROC, Annual report, Royal commission, Ovarian cancer, Therapy, Progression-free survival, MEC, ORR, Pharmaceutical industry

HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company),a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported financial results for the third quarter ended September 30, 2022 and provided corporate updates.

Key Points: 
  • HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company),a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported financial results for the third quarter ended September 30, 2022 and provided corporate updates.
  • Aravive continues to make tremendous progress on all fronts, said Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive.
  • The registration-directed Phase 3 program of batiraxcept in combination with paclitaxel in PROC remains on track to complete enrollment aroundyear-end 2022.
  • Revenues for the three months ended September30, 2022, were approximately $4.9 million, compared to approximately $1.6million for the three months ended June 30, 2022.

BioAtla to Participate in the Jefferies London Healthcare Conference

Retrieved on: 
Tuesday, November 8, 2022
SAN, GLOBE, Method, Conjugation, Conditional, Patent, Nasdaq, CAB, Antibody, Senior, Toxicity, Conference, AXL, Therapy, Pharmaceutical industry, Vaccine

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services.

Key Points: 
  • BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services.
  • Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal antibody and other protein therapeutic product candidates.
  • CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies.
  • BioAtla has extensive and worldwide patent coverage for its CAB technology and products with more than 600 patents, more than 350 of which are issued.

BioAtla Announces $65 Million Underwritten Offering of its Common Stock

Retrieved on: 
Friday, November 4, 2022
Janus, Conjugation, Research, Prospectus, Telephone, Therapy, J.P. Morgan & Co., Risk, SAN, LLC, SEC filing, Sale, Attention, Patent, Antibody, CAB, GLOBE, Method, AXL, Nasdaq, U.S. Securities and Exchange Commission, Broadridge Financial Solutions, Forward-looking statement, Form, Security (finance), Toxicity, Conditional, SEC, Pharmaceutical industry

The gross proceeds of the offering to BioAtla before deducting estimated underwriting discount and commissions and estimated offering expenses are expected to be approximately $65 million.

Key Points: 
  • The gross proceeds of the offering to BioAtla before deducting estimated underwriting discount and commissions and estimated offering expenses are expected to be approximately $65 million.
  • The offering is expected to close on or about November 8, 2022, subject to the satisfaction of customary closing conditions.
  • Investors in the offering include Acuta Capital Partners, Adage Capital Partners, Cormorant Asset Management, EcoR1 Capital, Janus Henderson Investors, Soleus Capital and Vivo Capital.
  • 333-262528) relating to the underwritten offering of the shares of common stock described above was previously filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on May 18, 2022.

BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022

Retrieved on: 
Thursday, October 27, 2022
Patent, Antibody, Investor, AXL, Method, Conjugation, Toxicity, News, Press release, CAB, Public relations, Vaccine, Fine chemical

A replay of the call will also be available through Events & Presentations in the Investors section of the companys website.

Key Points: 
  • A replay of the call will also be available through Events & Presentations in the Investors section of the companys website.
  • BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services.
  • Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal antibody and other protein therapeutic product candidates.
  • BioAtla has extensive and worldwide patent coverage for its CAB technology and products with more than 600 patents, more than 350 of which are issued.

Aravive Announces Approximately $41.5 Million Private Placement Financing

Retrieved on: 
Tuesday, October 25, 2022
Ovarian cancer, GAS6, Private Securities Litigation Reform Act, Terminology, Securities Act of 1933, Company, U.S. Securities and Exchange Commission, Cancer, Communication, GLOBE, Sale, Annual report, FDA, Tectonic evolution of the Aravalli Mountains, Patient, Quality of life, Platinum, SEC, DABT, Survival, Therapy, LLC, European Commission, PIPE, COVID-19, Paclitaxel, Risk, Exchange, Security (finance), Review, Forward-looking statement, Company Directors Disqualification Act 1986, Partnership, AXL, Doctor of Philosophy, Metastasis, European Network of Transmission System Operators for Electricity, Safety, Pharmaceutical industry, Nasdaq, PROC

The private placement is expected to close on October 27th, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The private placement is expected to close on October 27th, subject to the satisfaction of customary closing conditions.
  • The private placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the Minimum Price requirement (as defined in the Nasdaq rules).
  • MTS Securities, LLC, an affiliate of MTS Health Partners L.P., acted as the exclusive placement agent in the financing.
  • This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS

Retrieved on: 
Tuesday, October 25, 2022
Patient, Company, NSCLC, AXL, ASA, COVID-19, NOK, Pharmaceutical industry

BERGEN, Norway, Oct. 25, 2022 /PRNewswire/ --BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, and Meteva AS, a 27.23% shareholder in BerGenBio, today announced that they have entered into a shareholder loan facility, pursuant to which Meteva will make available to BerGenBio up to NOK 100 million.

Key Points: 
  • BERGEN, Norway, Oct. 25, 2022 /PRNewswire/ --BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, and Meteva AS, a 27.23% shareholder in BerGenBio, today announced that they have entered into a shareholder loan facility, pursuant to which Meteva will make available to BerGenBio up to NOK 100 million.
  • In addition to the cash position of NOK 225 million at the end of September 2022, this facility will enable BerGenBio to continue its previously announced focused strategy of advancing its lead compound bemcentinib in 1stline Non-Small Cell Lung Cancer (NSCLC) and hospitalized COVID-19 patients.
  • BerGenBio may, subject to certain conditions, draw on the facility from Q2 2023.
  • "We are truly grateful for the strong support of our largest shareholder, Meteva," stated Martin Olin, Chief Executive Officer of BerGenBio.

BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS

Retrieved on: 
Tuesday, October 25, 2022
Patient, Company, NSCLC, AXL, ASA, COVID-19, NOK, Pharmaceutical industry

BERGEN, Norway, Oct. 25, 2022 /PRNewswire/ --BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, and Meteva AS, a 27.23% shareholder in BerGenBio, today announced that they have entered into a shareholder loan facility, pursuant to which Meteva will make available to BerGenBio up to NOK 100 million.

Key Points: 
  • BERGEN, Norway, Oct. 25, 2022 /PRNewswire/ --BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, and Meteva AS, a 27.23% shareholder in BerGenBio, today announced that they have entered into a shareholder loan facility, pursuant to which Meteva will make available to BerGenBio up to NOK 100 million.
  • In addition to the cash position of NOK 225 million at the end of September 2022, this facility will enable BerGenBio to continue its previously announced focused strategy of advancing its lead compound bemcentinib in 1stline Non-Small Cell Lung Cancer (NSCLC) and hospitalized COVID-19 patients.
  • BerGenBio may, subject to certain conditions, draw on the facility from Q2 2023.
  • "We are truly grateful for the strong support of our largest shareholder, Meteva," stated Martin Olin, Chief Executive Officer of BerGenBio.

AAM to Announce Third Quarter Financial Results on November 4

Retrieved on: 
Friday, October 21, 2022
AAM, NYSE, Global Mobile Suppliers Association, AXL, Metal

DETROIT, Oct. 21, 2022 /PRNewswire/ -- American Axle & Manufacturing Holdings, Inc. (AAM), (NYSE: AXL) will hold a conference call to discuss third quarter and other related matters at 10:00 a.m.

Key Points: 
  • DETROIT, Oct. 21, 2022 /PRNewswire/ -- American Axle & Manufacturing Holdings, Inc. (AAM), (NYSE: AXL) will hold a conference call to discuss third quarter and other related matters at 10:00 a.m.
  • A press release announcing the results will be issued before the market opens on the same day and will be available at www.aam.com .
  • To participate by live audio webcast or listen to the briefing following the call, visit investor.aam.com.
  • Headquartered in Detroit with nearly 85 facilities in 18 countries, AAM is bringing the future faster for a safer and more sustainable tomorrow.